Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
Tesamorelin, marketed as Egrifta, Egrifta SV, and (as of March 2025) Egrifta WR, is a synthetic stabilized GHRH analog developed by Theratechnologies (Canada). It is the only FDA-approved GHRH analog currently marketed for therapeutic use (rather than diagnostic) and represents the most rigorously validated growth hormone-releasing factor analog in clinical practice. The FDA approval is specifically for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, a condition characterized by abnormal fat redistribution common in patients on antiretroviral therapy.
Tesamorelin is structurally distinct from sermorelin (which is the 1-29 fragment of GHRH). Tesamorelin contains the full 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminal tyrosine that protects against enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). This stabilization produces a half-life of approximately 26–38 minutes, substantially longer than native GHRH (~7 min) or sermorelin (~12 min), but shorter than CJC-1295 with DAC (~8 days).
FDA approval timeline:
| Date | Event |
|---|---|
| November 2010 | Egrifta approved by FDA for HIV-associated lipodystrophy |
| May 2019 | Egrifta SV (reformulated, simplified reconstitution) approved |
| March 2025 | Egrifta WR (tesamorelin F8) approved, reducing patient burden to weekly reconstitution |
The 2025 Egrifta WR approval is the most recent meaningful regulatory development in the GHRH analog space and represents continued investment in this therapy.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Subcutaneous tesamorelin (Egrifta, Egrifta SV: daily reconstitution) | ~26–38 minutes |
| Subcutaneous tesamorelin (Egrifta WR: weekly reconstitution, March 2025) | ~26–38 minutes (bioequivalent) |
What it does
Main effects
- Reduction of excess abdominal fat in HIV-associated lipodystrophy: the only FDA-approved indication; 15–18% mean visceral adipose tissue (VAT) reduction over 26 weeks of daily 2 mg subcutaneous dosing PMID: 18057338
- Visceral fat selectivity: substantial VAT reduction with minimal effect on subcutaneous fat; mechanistically distinct from GLP-1 receptor agonists (general weight loss) and direct GH (variable effects)
- Triglyceride reduction of approximately 50 mg/dL in pivotal Phase 3 trials
- Hepatic fat reduction: up to 20.4% relative reduction in hepatic fat fraction (Lo et al. 2020, non-HIV abdominal obesity, PMID 32086266); off-label evidence for MASLD/NAFLD applications
- GHRH receptor agonism: full 44-amino acid native GHRH sequence with trans-3-hexenoic acid N-terminal modification protecting against DPP-4 cleavage; half-life ~26–38 minutes (intermediate between sermorelin and CJC-1295 with DAC)
- ~80% IGF-1 elevation from baseline at 26 weeks: substantial but generally within acceptable range
- Modest lean mass preservation during VAT reduction
- Cognitive function benefits (research): improvements in verbal memory and executive function in HIV-positive patients (Marquine et al. 2014)
- Three FDA-approved formulations: Egrifta (2010, daily reconstitution), Egrifta SV (2019, simplified daily), Egrifta WR (March 2025, weekly reconstitution; most recent and convenient)
What to watch for
Common side effects
- Injection site reactions (pain, redness, swelling, induration): most common adverse effect; mild and self-limited; site rotation recommended
- Arthralgia (joint pain): mild to moderate; GH/IGF-1-related effect on connective tissue; more prominent than with shorter-acting GHRH analogs; usually manageable without discontinuation
- Peripheral edema: mild fluid retention; GH/IGF-1 related
- Pain in extremities: GH-related tissue effects
- Myalgia: mild muscle pain
- IGF-1 elevation: mean ~80% from baseline at 26 weeks; FDA labeling recommends monitoring with dose discontinuation if IGF-1 exceeds standard reference range (precautionary; no clinical adverse outcome correlated at standard doses)
- No significant effects on fasting glucose or HbA1c at 26 weeks in Phase 3 trials, though FDA labeling notes caution in diabetic patients
- Theoretical acromegaly-like effects with prolonged GH/IGF-1 elevation, not observed in trials at standard doses
- Theoretical cancer concerns: IGF-1's role in cell proliferation; active malignancy is a contraindication
- Rare carpal tunnel syndrome: uncommon with tesamorelin compared to high-dose direct GH
- CANNOT be lawfully compounded: biologic classification under BPCIA 2020; only brand-name Egrifta products are legally available; this distinguishes tesamorelin from sermorelin/CJC-1295/ipamorelin/GHRPs
- Significant cost at list price, and insurance often covers it only for the approved HIV lipodystrophy indication
- Contraindications: disrupted hypothalamic-pituitary axis (pituitary tumor, surgery, head irradiation, head trauma), active malignancy, pregnancy, hypersensitivity to tesamorelin or mannitol
- WADA-prohibited under category S2
Key facts
Key facts worth knowing
- Tesamorelin is the only FDA-approved GHRH analog currently in commercial production. This distinguishes it from sermorelin (FDA-approved in 1990 but commercial product discontinued 2008) and CJC-1295 (Phase 2 development halted after patient death). For users wanting GHRH-based therapy with rigorous regulatory validation, tesamorelin is the only currently available FDA-approved option.
- Pivotal Phase 3 trial (Falutz et al. 2007, NEJM) enrolled 412 HIV-infected adults with lipodystrophy. Demonstrated 15–18% mean reduction in visceral adipose tissue (VAT) over 26 weeks of daily 2 mg subcutaneous dosing. Triglycerides reduced ~50 mg/dL on average. This is the strongest visceral fat reduction evidence of any peptide therapy. PMID: 18057338
- 52-week safety extension trial extended observations to one year. Reported no new safety signals; injection-site reactions remained the dominant adverse event. PMID: 20101189PMID: 18931593
- 80% mean IGF-1 elevation from baseline at 26 weeks: substantial but generally within acceptable range. FDA labeling recommends IGF-1 monitoring and dose-discontinuation if IGF-1 exceeds standard reference range thresholds (precautionary).
- Lo et al. 2020 (Diabetes Care): Non-HIV trial in 60 adults with abdominal obesity. Tesamorelin reduced VAT by 21.6 cm² and hepatic fat fraction by 20.4% relative reduction. Off-label evidence for general abdominal obesity and NAFLD/MASLD applications, though not sufficient for additional FDA approval. PMID: 32086266
- Cognitive benefits research: Studies have explored tesamorelin's effects on cognitive function in HIV-positive patients (Marquine et al. 2014) and aging adults, with some evidence of improved verbal memory and executive function.
- Classified as a biologic under federal law (BPCIA, 2020). This cannot be lawfully produced through pharmacy compounding under Section 503A. Only the FDA-approved Egrifta product is legally available in the United States. This is a critical regulatory distinction from sermorelin, CJC-1295, ipamorelin, and other GHRH/GHRP peptides that have been available through compounding pharmacies.
- Mechanism is GHRH receptor agonism on pituitary somatotrophs: same fundamental receptor as sermorelin and CJC-1295, with sustained release pattern (intermediate between sermorelin's pulses and CJC-1295 DAC's chronic elevation). WADA Prohibited under category S2.
Legal status
Legal status
FDA-approved as Egrifta (2010), Egrifta SV (2019), and Egrifta WR (March 2025) for HIV-associated lipodystrophy. Off-label prescribing of the approved product is permitted under medical practice. Cannot legally be compounded (biologic classification under BPCIA 2020). Research chemical sale exists in legal grey area but is technically not legal for human use. Not a controlled substance. WADA-prohibited under category S2.